Multicentre study of 18F-FDG-PET/CT prostate incidental uptake.
Details
Serval ID
serval:BIB_C4AC2B34535D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Multicentre study of 18F-FDG-PET/CT prostate incidental uptake.
Journal
Japanese journal of radiology
ISSN
1867-108X (Electronic)
ISSN-L
1867-1071
Publication state
Published
Issued date
09/2015
Peer-reviewed
Oui
Volume
33
Number
9
Pages
538-546
Language
english
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Publication Status: ppublish
Abstract
The purpose of our study was to establish the prevalence and pathological nature of fluorine-18-fluorodeoxyglucose (18F-FDG) prostate incidental uptake (PIU) among patients studied for non-prostate-malignant purposes in three nuclear medicine centres.
We retrospectively evaluated 20,422 scans performed on male patients; all patients underwent 18F-FDG-PET/CT for purposes not related to prostate disease.
Among 20,422 patients PIU was identified for 280 (1.4 %) with an average age of 70 ± 10.7 years. Sixty-three of the 280 patients with PIU (22.5 %) underwent PSA dosage and biopsy to determine the nature of the incidental uptake. Thirty-five of the 63 (55.5 %) PIU were malignant whereas 28/63 (44.5 %) were benign. The average value of PSA for patients with benign PIU was 3.7 ± 2.8 ng/ml whereas it was 7.8 ± 8.2 ng/ml in patients with malignant PIU; this difference was statistically significant. For malignant lesions, the average lesion-to-liver SUVmax ratio was 2.9 ± 2.5 and the average lesion-to-blood-pool SUVmax ratio was 3.7 ± 2.5. For benign lesions, the average lesion-to-liver SUVmax ratio was 2.5 ± 1.7 and the average lesion-to-blood-pool SUVmax ratio was 3.5 ± 2.4; there was no statistically significant difference between lesion-to-liver and lesion-to-blood-pool SUVmax ratios for benign and malignant lesions.
Because PIU values are indicative of malignancy for a substantial percentage of patients, further investigation is required.
We retrospectively evaluated 20,422 scans performed on male patients; all patients underwent 18F-FDG-PET/CT for purposes not related to prostate disease.
Among 20,422 patients PIU was identified for 280 (1.4 %) with an average age of 70 ± 10.7 years. Sixty-three of the 280 patients with PIU (22.5 %) underwent PSA dosage and biopsy to determine the nature of the incidental uptake. Thirty-five of the 63 (55.5 %) PIU were malignant whereas 28/63 (44.5 %) were benign. The average value of PSA for patients with benign PIU was 3.7 ± 2.8 ng/ml whereas it was 7.8 ± 8.2 ng/ml in patients with malignant PIU; this difference was statistically significant. For malignant lesions, the average lesion-to-liver SUVmax ratio was 2.9 ± 2.5 and the average lesion-to-blood-pool SUVmax ratio was 3.7 ± 2.5. For benign lesions, the average lesion-to-liver SUVmax ratio was 2.5 ± 1.7 and the average lesion-to-blood-pool SUVmax ratio was 3.5 ± 2.4; there was no statistically significant difference between lesion-to-liver and lesion-to-blood-pool SUVmax ratios for benign and malignant lesions.
Because PIU values are indicative of malignancy for a substantial percentage of patients, further investigation is required.
Keywords
Aged, Fluorodeoxyglucose F18/pharmacokinetics, Humans, Incidental Findings, Male, Middle Aged, Multimodal Imaging, Positron-Emission Tomography, Prostate/diagnostic imaging, Prostatic Neoplasms/diagnosis, Radiopharmaceuticals/pharmacokinetics, Retrospective Studies, Tomography, X-Ray Computed, 18F-FDG, Incidentaloma, PET/CT, Prostate
Pubmed
Web of science
Create date
20/08/2017 16:59
Last modification date
20/08/2019 15:40